Walgreens had contracted with PWNHealth early in the COVID-19 pandemic when ordering a COVID-19 test required a physician’s involvement. Walgreens used PWNHealth’s network of physicians to ...

PWNHealth and Home Access Health offer self-collected lab testing services. The new company, Everly Health, will support more than 20 million people in all 50 U.S. states, Canada and Puerto Rico ...

At the beginning of 2020, during the COVID-19 pandemic, ordering a COVID-19 test required a physician's involvement. Walgreens contracted with PWNHealth to use its physician network to order COVID ...

Everly Health’s business now includes not only that kind of at-home consumer diagnostic and personal health education, but also many relationships through PWNHealth, which will rebrand to Everly ...

PWNHealth, which is a subsidiary of Everlywell, a digital health company, is an independent telemedicine vendor which reviews Galleri test requests, ...

PWNHealth (PWN) is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth.

PWNHealth today announced that its national testing platform has supported more than 5 million COVID-19 PCR and antibody tests since April 2020.

PWNHealth, a provider of healthcare diagnostic testing enablement solutions, has secured a “significant” investment led by Spectrum Equity. Other investors were Blue Venture Fund and Sandbox ...

PWNHealth — a virtual care company focused on diagnostic testing, treatment and guidance — provides its genetic counseling services through phone and video conferencing.

The vendor, PWNHealth, notified Grail on May 19 that an “inaccurate form letter” had been sent to roughly 400 customers from May 10 to May 18, Grail said in its statement.

Retail pharmacy giant Walgreen Co must pay more than $987 million to satisfy an arbitration award won by telemedicine provider PWNHealth, a federal judge in Delaware ruled on Monday.

More than 400 patients who signed up to take a pioneering oncology detection test developed by US biotech company Grail received erroneous letters last month suggesting they may have developed ...